Two Years of Ofatumumab Reshapes the Immune Landscape in Multiple Sclerosis
A two-year real-world study found that ofatumumab sustained B-cell depletion in multiple sclerosis patients while producing significant increases in broad ...
A two-year real-world study found that ofatumumab sustained B-cell depletion in multiple sclerosis patients while producing significant increases in broad ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.